Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU
| Autor: | Vigon-Hernandez, Lorena, García-Pérez, Javier, Rodríguez-Mora, Sara, Torres, Montserrat, Mateos, Elena, Castillo de la Osa, María, Cervero, Miguel, Malo De Molina, Rosa, Navarro, Cristina, Murciano-Antón, María Aránzazu, García-Gutiérrez, Valentín, Planelles, Vicente, Alcamí, José, Perez-Olmeda, Mayte, Coiras, Mayte, Lopez-Huertas, Maria Rosa, Multidisciplinary Group of Study of COVID-19 (MGS-COVID) |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Ministerio de Economía y Competitividad (España), Red de Investigación Cooperativa en Investigación en Sida, Plan Nacional de I+D+i (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), National Institutes of Health (Estados Unidos) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Antibody-dependent cellular cytotoxicity (ADCC) Cross-sectional study Immunology Disease Antibodies Viral Cohort Studies Immune system Pandemic Immunology and Allergy Medicine Humans Humoral response Aged Original Research Antibody-dependent cell-mediated cytotoxicity Aged 80 and over EBV reactivation biology CMV reactivation business.industry SARS-CoV-2 antibody-dependent cellular cytotoxicity (ADCC) Antibody-Dependent Cell Cytotoxicity virus diseases COVID-19 SARS-CoV-2 neutralizing antibodies RC581-607 Middle Aged COVID-19 severity Hospitalization Intensive Care Units Cross-Sectional Studies Spain Cohort biology.protein Female Immunologic diseases. Allergy Antibody business humoral response Cohort study |
| Zdroj: | Frontiers in Immunology Frontiers in Immunology, Vol 12 (2021) Repisalud Instituto de Salud Carlos III (ISCIII) |
| Popis: | SARS-CoV-2 infection causes COVID-19, ranging from mild to critical disease in symptomatic subjects. It is essential to better understand the immunologic responses occurring in patients with the most severe outcomes. In this study, parameters related to the humoral immune response elicited against SARS-CoV-2 were analysed in 61 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centres in Madrid, Spain, during the first pandemic peak between April and June 2020. Subjects were allocated as mild patients without hospitalization, severe patients hospitalized or critical patients requiring ICU assistance. Critical patients showed significantly enhanced levels of B cells with memory and plasmablast phenotypes, as well as higher levels of antibodies against SARS-CoV-2 with neutralization ability, which were particularly increased in male gender. Despite all this, antibody-dependent cell-mediated cytotoxicity was defective in these individuals. Besides, patients with critical COVID-19 also showed increased IgG levels against herpesvirus such as CMV, EBV, HSV-1 and VZV, as well as detectable CMV and EBV viremia in plasma. Altogether, these results suggest an enhanced but ineffectual immune response in patients with critical COVID-19 that allowed latent herpesvirus reactivation. These findings should be considered during the clinical management of these patients due to the potential contribution to the most severe disease during SARS-CoV-2 infection. This work was supported by the Coordinated Research Activities at the Centro Nacional de Microbiología (CNM, Instituto de Salud Carlos III) (COV20_00679) to promote an integrated response against SARS-CoV-2 in Spain (Spanish Ministry of Science and Innovation) that is coordinated by Dr Inmaculada Casas (WHO National Influenza Center of the CNM) and a generous donation provided by Chiesi España, S.A.U. (Barcelona, Spain). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. This work was also supported by the Spanish Ministry of Economy and Competitiveness (PID2019 110275RB-I00); the Spanish AIDS Research Network RD16CIII/0002/0001 that is included in Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2016-2020, Instituto de Salud Carlos III, European Region Development Fund (ERDF); Miguel Servet - AESI, MPY 341/21. The work of ML-H and SR is financed by NIH grant R01AI143567. The work of MT is supported by Instituto de Salud Carlos III (COV20_00679). The work of LV is supported by a predoctoral grant from Instituto de Salud Carlos III (FIS PI16CIII/00034-ISCIII-FEDER). Sí |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|